Postmenopausal women with hormone receptor-positive breast cancer: Balancing benefit and toxicity from aromatase inhibitors

Breast

Volumn 22, Issue S2, 2013, Pages

  Ingle, James N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Breast cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN;

AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; COMORBIDITY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DRUG EFFICACY; DRUG INFORMATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EVENT FREE SURVIVAL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

ADJUVANT THERAPY; AROMATASE INHIBITORS; BREAST CANCER; TAMOXIFEN;

AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, ADJUVANT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 84883402514     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.035     Document Type: Article

References (25)

1. Ingle J.N. Overview of adjuvant trials of aromatase inhibitors in early breast cancer. Steroids 2011, 76(8):765-767.
2. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. Early Breast Cancer Trialists' Collaborative Group.
3. Burstein H.J., Prestrud A.A., Seidenfeld J., Anderson H., Buchholz T.A., Davidson N.E., et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. JClin Oncol 2010, 28:3784-3796.
4. Cuzick J., Sestak I., Cella D., Fallowfield L. Treatment-emergent endocrine symptoms and the risk a breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9:1143-1148.
5. Fontein D.B.Y., Houtsma D., Hille E.T.M., Seynaeve C., Putter H., Meerhoek-Klein E., et al. Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients. Ann Oncol 2012, 23:3091-3097.
6. Stearns V., Chapman J.A.W., Ma S.X., Ellis M.J., Ingle J.N., Pritchard K.I., et al. Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. JClin Oncol 2011, 29:45s. [abstract 525].
7. Cella D., Fallowfield L., Barker P., Cuzick J., Locker G., Howell A. Quality of life of postmenopausal women in the ATAC ("Arimidex", Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006, 100:273-284.
8. Van Nes J.G.H., Fontein D.B.Y., Hille E.T.M., Voskuil D.W., van Loeuwen F.E., de Haes J.C.J.M., et al. Quality of life in relation to tamoxifen or ezemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial side study. Breast Cancer Res Treat 2012, 134:267-276.
9. Whelan T.J., Goss P.E., Ingle J.N., Pater J.L., Tu D.S., Pritchard K.I., et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. JClin Oncol 2005, 23:6931-6940.
10. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. JClin Oncol 2010, 28:509-518.
11. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. JNatl Cancer Inst 2005, 97:1262-1271.
12. Mamounas E.P., Jeong J.H., Wickerham D.L., Smith R.E., Ganz P.A., Land S.R., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. JClin Oncol 2008, 26:1965-1971.
13. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381:805-816.
14. Amir E., Seruga B., Niraula S., Carlsson L., Ocańa A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. JNatl Cancer Inst 2011, 103:1299-1309.
15. Colleoni M., Giobbie-Hurder A., Regan M.M., Thurlimann B., Mouridsen H., Mauriac L., et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. JClin Oncol 2011, 29:1117-1124.
16. Goss P.E., Ingle J.N., Pritchard K.I., Ellis M.J., Sledge G.W., Budd G.T., et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27, a randomized, controlled phase III trial. JClin Oncol 2013, 31:1398-1404.
17. Extermann M., Balducci L., Lyman G.H. What threshold for adjuvant therapy in older breast cancer patients?. JClin Oncol 2000, 18:1709-1717.
18. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. JChronic Dis 1987, 40:373-383.
19. Satariano W.A., Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994, 120:104-110.
20. Chapman J.A., Meng D., Shepherd L., Parulekar W., Ingle J.N., Muss H.B., et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. JNatl Cancer Inst 2008, 100:252-260.
21. Ring A., Sestak I., Baum M., Howell A., Buzdar A., Dowsett M., et al. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen alone or in combination trial. JClin Oncol 2011, 32:4266-4272.
22. Ravdin P.M., Siminoff L.A., Davis G.J., Mercer M.B., Hewlett S., Gerson N., et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. JClin Oncol 2001, 19:980-991.
23. Ingle J.N., Schaid D.J., Goss P.E., Liu M., Mushiroda T., Chapman J.A., et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. JClin Oncol 2010, 28:4674-4682.
24. Liu M., Wang L., Bongartz T., Hawse J.R., Markovic S.N., Schaid D.J., et al. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res 2012, 14:R41.
25. Offit K., Robson M.E. New pharmacogenomic paradigm in breast cancer treatment. JClin Oncol 2010, 28:4665-4666.